JP2015522617A5 - - Google Patents

Download PDF

Info

Publication number
JP2015522617A5
JP2015522617A5 JP2015523185A JP2015523185A JP2015522617A5 JP 2015522617 A5 JP2015522617 A5 JP 2015522617A5 JP 2015523185 A JP2015523185 A JP 2015523185A JP 2015523185 A JP2015523185 A JP 2015523185A JP 2015522617 A5 JP2015522617 A5 JP 2015522617A5
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
acceptable salt
compound
disease
dementia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015523185A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015522617A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/050719 external-priority patent/WO2014014937A1/en
Publication of JP2015522617A publication Critical patent/JP2015522617A/ja
Publication of JP2015522617A5 publication Critical patent/JP2015522617A5/ja
Pending legal-status Critical Current

Links

JP2015523185A 2012-07-16 2013-07-16 タンパク質凝集の阻害剤としてのジ−およびトリ−ヘテロアリール誘導体 Pending JP2015522617A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261672239P 2012-07-16 2012-07-16
US61/672,239 2012-07-16
PCT/US2013/050719 WO2014014937A1 (en) 2012-07-16 2013-07-16 Di-and tri-heteroaryl derivatives as inhibitors of protein aggregation

Publications (2)

Publication Number Publication Date
JP2015522617A JP2015522617A (ja) 2015-08-06
JP2015522617A5 true JP2015522617A5 (https=) 2016-09-01

Family

ID=49949212

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015523185A Pending JP2015522617A (ja) 2012-07-16 2013-07-16 タンパク質凝集の阻害剤としてのジ−およびトリ−ヘテロアリール誘導体

Country Status (15)

Country Link
US (1) US9284309B2 (https=)
EP (1) EP2872143B1 (https=)
JP (1) JP2015522617A (https=)
KR (1) KR20150031481A (https=)
CN (1) CN104703604A (https=)
AU (1) AU2013290361A1 (https=)
BR (1) BR112015001096A2 (https=)
CA (1) CA2877983A1 (https=)
ES (1) ES2661394T3 (https=)
HK (1) HK1210598A1 (https=)
IL (1) IL236712A0 (https=)
IN (1) IN2015DN01171A (https=)
MX (1) MX2015000618A (https=)
RU (1) RU2015104962A (https=)
WO (1) WO2014014937A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP2016009347A0 (en) * 2014-01-29 2016-07-31 Neuropore Therapies Inc Heteroarly amides as inhibitors of protein aggregation
EP3328379B1 (en) * 2015-07-29 2021-07-28 UCB Biopharma SRL Bis-heteroaryl derivatives as modulators of protein aggregation
EA201991755A1 (ru) 2017-01-26 2020-01-22 Юсб Байофарма Спрл Бициклические бисгетероарильные производные в качестве модуляторов агрегации белков
CN110198938B (zh) 2017-01-26 2023-03-14 Ucb生物制药私人有限公司 作为蛋白质聚集调节剂的双-杂芳基衍生物
KR20190112031A (ko) * 2017-01-26 2019-10-02 유씨비 바이오파마 에스피알엘 단백질 응집의 조절제로서의 알콕시 비스-헤테로아릴 유도체
WO2018158160A1 (en) 2017-02-28 2018-09-07 Universitat Autonoma De Barcelona (nitro-phenyl)-nitropyridine compounds for treating synucleinopathies
WO2019025424A1 (en) 2017-08-04 2019-02-07 Universitat Autonoma De Barcelona COMPOUNDS FOR TREATING SYNUCLEINOPATHIES
WO2019161917A1 (en) 2018-02-23 2019-08-29 Universitat Autonoma De Barcelona 4-substituted 1-ethenylsulfonyl-2-nitrobenzene compounds for treating synucleinopathies
CN113683598B (zh) * 2020-05-18 2022-10-14 成都先导药物开发股份有限公司 一种免疫调节剂
WO2025223458A1 (zh) * 2024-04-23 2025-10-30 深圳众格生物科技有限公司 一种cyp11a1抑制剂、其制备方法及其应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4739632B2 (ja) 2000-02-05 2011-08-03 バーテックス ファーマシューティカルズ インコーポレイテッド Erkのインヒビターとして有用なピラゾール組成物
EP1317453B1 (en) 2000-09-15 2006-08-09 Vertex Pharmaceuticals Incorporated Isoxazoles and their use as inhibitors of erk
AU2003257094A1 (en) * 2002-08-08 2004-02-25 Boehringer Ingelheim Pharmaceuticals, Inc. Substituted benzimidazole compounds
LT2899191T (lt) 2009-04-30 2017-10-25 Glaxo Group Limited Oksazolo pakeistieji indazolai kaip pi3-kinazės inhibitoriai
GB0910003D0 (en) * 2009-06-11 2009-07-22 Univ Leuven Kath Novel compounds for the treatment of neurodegenerative diseases
KR20120112548A (ko) * 2009-12-16 2012-10-11 뉴로포레 테라피스, 인코포레이티드 시누클레인 병을 치료하는데 적합한 화합물
US9198891B2 (en) * 2010-05-21 2015-12-01 New York University Method of treating cancer by inhibition of protein kinase-like endoplasmic reticulum protein kinase

Similar Documents

Publication Publication Date Title
JP2015522617A5 (https=)
JP2011088926A5 (https=)
JP2019524883A5 (https=)
EP2872143B1 (en) Di-and tri-heteroaryl derivatives as inhibitors of protein aggregation
JP2018519323A5 (https=)
IN2012DE00337A (https=)
JP2011132222A5 (https=)
JP2013542261A5 (https=)
JP2014511892A5 (https=)
EA201391263A1 (ru) Комбинированные терапии гематологических опухолей
JP2017526727A5 (https=)
JP2014521744A5 (https=)
CA2514384A1 (en) 1-phenylalkanecarboxylic acid derivatives for the treatment of neurodegenerative diseases
JP2012513416A5 (https=)
JP2017534665A5 (https=)
JP2016511753A5 (https=)
JP2015535847A5 (https=)
JP2016513696A5 (https=)
JP2017534663A5 (https=)
JP2018537513A5 (https=)
JP2016529235A5 (https=)
NZ603108A (en) 3-(heteroaryl-amino)-1,2,3,4-tetrahydro-9h-carbazole derivatives and their use as prostaglandin d2 receptor modulators
RU2016104844A (ru) Производные n-мочевино замещенных аминокислот как модуляторы формил-пептидного рецептора
JP2011046708A5 (https=)
JP2016537432A5 (https=)